Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Current Taxes (2017 - 2019)

Avalo Therapeutics (AVTX) has disclosed Current Taxes for 3 consecutive years, with $551671.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Current Taxes fell 72.85% year-over-year to $551671.0, compared with a TTM value of $551671.0 through Dec 2019, down 72.85%, and an annual FY2019 reading of $551671.0, down 72.85% over the prior year.
  • Current Taxes was $551671.0 for Q4 2019 at Avalo Therapeutics, down from $1.0 million in the prior quarter.
  • Across five years, Current Taxes topped out at $3.2 million in Q3 2017 and bottomed at $551671.0 in Q4 2019.
  • Average Current Taxes over 3 years is $1.9 million, with a median of $2.1 million recorded in 2018.
  • The sharpest move saw Current Taxes decreased 10.04% in 2018, then tumbled 72.85% in 2019.
  • Year by year, Current Taxes stood at $2.3 million in 2017, then fell by 10.04% to $2.0 million in 2018, then crashed by 72.85% to $551671.0 in 2019.
  • Business Quant data shows Current Taxes for AVTX at $551671.0 in Q4 2019, $1.0 million in Q3 2019, and $1.4 million in Q2 2019.